{
  "id": "topic6",
  "title": "Topic 6: Specialized Organ Systems - Comprehensive Board Study Guide",
  "description": "[‚¨ÜÔ∏è Back to Master Index](study-guide-master-index.",
  "difficulty": "Advanced",
  "tags": [
    "specialized",
    "rare",
    "complex"
  ],
  "estimatedTime": 28,
  "importance": 1,
  "sections": [
    {
      "id": "quick-navigation",
      "title": "Quick Navigation",
      "content": "**[‚¨ÜÔ∏è Back to Master Index](study-guide-master-index.md)** | **[‚¨ÖÔ∏è Previous: Metabolic Disorders](topic5-metabolic-disorders.md)**\n\n### üìã Table of Contents\n- [üéØ Learning Objectives](#-learning-objectives)\n- [üìä Overview of Specialized Systems](#-overview-of-specialized-systems)\n- [üé® Dermatologic Disorders](#-dermatologic-disorders)\n  - [Incontinentia Pigmenti (IP) ‚≠ê‚≠ê‚≠ê](#incontinentia-pigmenti-ip-)\n  - [Ectodermal Dysplasias ‚≠ê‚≠ê](#ectodermal-dysplasias-)\n  - [Albinism ‚≠ê‚≠ê](#albinism-)\n  - [Epidermolysis Bullosa (EB) ‚≠ê‚≠ê](#epidermolysis-bullosa-eb-)\n- [ü¶¥ Skeletal/Connective Tissue Disorders](#-skeletalconnective-tissue-disorders)\n  - [Osteogenesis Imperfecta (OI) ‚≠ê‚≠ê‚≠ê](#osteogenesis-imperfecta-oi-)\n  - [Marfan Syndrome ‚≠ê‚≠ê‚≠ê](#marfan-syndrome-)\n  - [Ehlers-Danlos Syndromes (EDS) ‚≠ê‚≠ê‚≠ê](#ehlers-danlos-syndromes-eds-)\n  - [Achondroplasia ‚≠ê‚≠ê‚≠ê](#achondroplasia-)\n- [üëÇ Sensory Disorders](#-sensory-disorders)\n  - [Hereditary Hearing Loss ‚≠ê‚≠ê‚≠ê](#hereditary-hearing-loss-)\n  - [Hereditary Vision Loss ‚≠ê‚≠ê](#hereditary-vision-loss-)\n- [üî¨ Endocrine Disorders](#-endocrine-disorders)\n  - [Congenital Adrenal Hyperplasia (CAH) ‚≠ê‚≠ê‚≠ê](#congenital-adrenal-hyperplasia-cah-)\n- [ü©∏ Hematological Disorders](#-hematological-disorders)\n  - [Hemoglobinopathies ‚≠ê‚≠ê‚≠ê](#hemoglobinopathies-)\n  - [Bleeding Disorders ‚≠ê‚≠ê‚≠ê](#bleeding-disorders-)\n- [üß¨ DNA Repair/Premature Aging Disorders](#-dna-repairpremature-aging-disorders)\n  - [Bloom Syndrome ‚≠ê‚≠ê](#bloom-syndrome-)\n  - [Xeroderma Pigmentosum (XP) ‚≠ê‚≠ê](#xeroderma-pigmentosum-xp-)\n  - [Fanconi Anemia (FA) ‚≠ê‚≠ê‚≠ê](#fanconi-anemia-fa-)\n- [üìã High-Yield Board Facts](#-high-yield-board-facts)\n- [üßÆ Practice Questions](#-practice-questions)\n- [üìù Mnemonics & Memory Aids](#-mnemonics--memory-aids)\n- [‚úÖ Topic 6 Completion Checklist](#-topic-6-completion-checklist)\n\n### üîç Quick Disorder Lookup\n| Disorder | Key Features | Inheritance | Population Risk | Management |\n|----------|--------------|-------------|-----------------|------------|\n| **Incontinentia Pigmenti** | Staged skin lesions, seizures | XLD, male lethal | Sporadic/familial | Neurologic monitoring |\n| **Hypohidrotic ED** | No sweating, teeth/hair abnormal | XLR | 1:100,000 | Heat protection |\n| **Osteogenesis Imperfecta** | Multiple fractures, blue sclerae | AD (mostly) | 1:20,000 | Fracture prevention |\n| **Marfan Syndrome** | Aortic dilatation, lens dislocation | AD | 1:5,000 | Cardiac monitoring |\n| **Achondroplasia** | Rhizomelic dwarfism | AD, de novo | 1:25,000 | Growth monitoring |\n| **GJB2 Hearing Loss** | Congenital deafness | AR | 1:1,000 | Early intervention |\n| **CAH** | Ambiguous genitalia, salt wasting | AR | 1:15,000 | Hormone replacement |\n| **Sickle Cell Disease** | Vaso-occlusive crises | AR | 1:365 (AA) | Hydroxyurea, prophylaxis |\n| **Hemophilia A** | Bleeding, joint hemorrhages | XLR | 1:5,000 males | Factor replacement |\n| **Bloom Syndrome** | Growth deficiency, cancer risk | AR | 1:48,000 (AJ) | Cancer surveillance |\n\n### üèÜ Board Exam Domain Coverage\n- **Primary Domain:** Clinical Genetics (40-50%)\n- **Secondary Domains:** General Genetics/Genomics (15-25%), Psychosocial/Counseling (10-20%)\n- **Difficulty Level:** Intermediate to Advanced\n- **Estimated Study Time:** 12-15 hours\n- **Last Updated:** July 2025\n\n---",
      "importance": 1
    },
    {
      "id": "learning-objectives",
      "title": "Learning Objectives",
      "content": "By the end of this topic, you should be able to:\n\n1. **Identify** population-specific carrier screening programs for hemoglobinopathies and their target populations\n2. **Counsel** families about CAH newborn screening results and follow-up protocols\n3. **Recognize** prenatal diagnosis challenges for skeletal dysplasias on ultrasound\n4. **Apply** genetic counseling principles for sensory impairments while respecting deaf culture\n5. **Evaluate** pregnancy management strategies for women with connective tissue disorders\n6. **Calculate** carrier risks for X-linked bleeding disorders and counsel at-risk family members\n7. **Develop** cancer surveillance protocols for DNA repair disorder patients\n8. **Compare** quality of life considerations across chronic genetic conditions\n9. **Interpret** hemoglobin electrophoresis results and explain implications\n10. **Distinguish** between different types of ectodermal dysplasias and their inheritance patterns\n11. **Assess** reproductive options for couples at risk for severe skeletal dysplasias\n12. **Demonstrate** cultural competency when counseling for sensory and skin disorders\n\n---",
      "importance": 1
    },
    {
      "id": "overview-of-specialized-systems",
      "title": "Overview of Specialized Systems",
      "content": "<details>\n<summary><strong>üìã Major Categories Covered</strong> (Click to expand)</summary>\n\n### Major Categories Covered\n1. **Dermatologic Disorders** - Skin, hair, nail abnormalities\n2. **Skeletal/Connective Tissue** - Bone, joint, vessel disorders\n3. **Sensory Disorders** - Vision and hearing impairments\n4. **Endocrine Disorders** - Hormone deficiencies/excess\n5. **Hematological Disorders** - Blood cell/clotting abnormalities\n6. **DNA Repair/Premature Aging** - Cancer predisposition syndromes\n\n### Key Board Exam Themes\n- Population-based screening programs\n- Newborn screening protocols\n- Prenatal diagnosis limitations\n- Cultural considerations in counseling\n- Reproductive planning for chronic conditions\n- Cancer surveillance guidelines\n- Quality of life assessments\n\n</details>\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)**\n\n---",
      "importance": 1
    },
    {
      "id": "dermatologic-disorders",
      "title": "\udfa8 DERMATOLOGIC DISORDERS",
      "content": "### Incontinentia Pigmenti (IP) ‚≠ê‚≠ê‚≠ê\n**X-linked Dominant with Male Lethality**\n\n#### üîë Key Features (Top 3)\n1. **Staged skin findings** (4 stages)\n2. **Ectodermal dysplasia signs**\n3. **Risk for seizures**\n\n<details>\n<summary><strong>üè• Clinical Features</strong> (Click to expand)</summary>\n\n- **Stage 1 (birth-4mo)**: Linear blistering along Blaschko lines\n- **Stage 2 (2-6mo)**: Warty/verrucous lesions\n- **Stage 3 (6mo-adult)**: Swirling hyperpigmentation\n- **Stage 4 (adult)**: Linear hypopigmentation/atrophy\n- **Ectodermal**: Alopecia, cone-shaped teeth, nail dystrophy\n- **Neurologic**: Seizures (30%), ID if seizures occur\n- **Ocular**: Retinal detachment, vision loss\n\n</details>\n\n<details>\n<summary><strong>üß™ Genetics & Testing</strong> (Click to expand)</summary>\n\n- **Gene**: IKBKG (NEMO) at Xq28\n- **Inheritance**: X-linked dominant\n- **Testing**: \n  - Gene sequencing (65% detection)\n  - Deletion/duplication analysis\n  - Skin biopsy shows eosinophils\n- **Mosaicism**: Common in affected females\n\n</details>\n\n<details>\n<summary><strong>üë∂ Reproductive Counseling</strong> (Click to expand)</summary>\n\n- **Affected females**: \n  - 50% affected daughters (may be milder due to skewing)\n  - 50% affected sons (usually lethal in utero)\n  - 25% unaffected daughters\n  - 25% unaffected sons\n- **Prenatal findings**: Possible male hydrops\n- **X-inactivation**: May ameliorate severity\n\n</details>\n\n#### üíé Board Pearls\n- Blaschko lines = developmental migration patterns\n- Male lethality leads to skewed sex ratio\n- Stages don't always occur in order\n- X-inactivation studies helpful for carriers\n- Consider if multiple miscarriages + skin findings\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Ectodermal Dysplasias](#ectodermal-dysplasias-)**\n\n---\n\n### Ectodermal Dysplasias ‚≠ê‚≠ê\n\n#### Hypohidrotic Ectodermal Dysplasia (HED)\n**X-linked > AR, AD**\n\n##### üîë Key Features (Top 3)\n1. **Absent/reduced sweating** ‚Üí heat intolerance\n2. **Abnormal teeth** (peg-shaped, missing)\n3. **Sparse hair**\n\n##### üè• Clinical Features\n- **Classic triad**: Hypohidrosis, hypotrichosis, hypodontia\n- **Facial**: Frontal bossing, depressed nasal bridge, thick lips\n- **Dangerous**: Hyperthermia risk (especially infants)\n- **Other**: Dry skin, decreased tears, respiratory infections\n\n##### üß™ Genetics & Testing\n- **X-linked (most common)**: EDA gene\n- **AR**: EDAR, EDARADD\n- **AD**: EDAR, EDARADD (less severe)\n- **Carrier females**: May have patchy sweating, dental anomalies\n\n##### üíé Board Pearls\n- Infant boys with \"fever of unknown origin\" ‚Üí check sweating\n- Carrier females: Lyon hypothesis creates mosaic features\n- Dental implants often needed\n- Heat stroke prevention critical\n\n#### Clouston Syndrome (Hidrotic ED)\n**AD, Normal Sweating**\n\n- **Key features**: Normal sweating, total alopecia, nail dystrophy\n- **Gene**: GJB6 (connexin 30)\n- **Distinguishing**: Palmoplantar hyperkeratosis\n- **Board pearl**: They DO sweat (unlike HED)\n\n---\n\n### Albinism ‚≠ê‚≠ê\n\n#### Oculocutaneous Albinism (OCA)\n**AR, Multiple Types**\n\n##### üîë Key Features (Top 3)\n1. **Hypopigmentation** of skin, hair, eyes\n2. **Vision impairment** (nystagmus, photophobia)\n3. **Increased skin cancer risk**\n\n##### Types & Genes\n- **OCA1**: TYR gene\n  - OCA1A: Complete absence of melanin\n  - OCA1B: Some pigment develops with age\n- **OCA2**: OCA2 gene (most common worldwide)\n- **OCA3**: TYRP1 (rare, \"rufous\" albinism in Africa)\n- **OCA4**: SLC45A2 (common in Japan)\n\n##### üè• Management\n- **Ophthalmology**: Regular exams, low vision aids\n- **Dermatology**: Sun protection, skin cancer screening\n- **Psychosocial**: Address stigma, especially in Africa\n\n##### üíé Board Pearls\n- Visual pathway misrouting is pathognomonic\n- Carrier testing difficult due to multiple genes\n- Higher prevalence in certain populations:\n  - OCA2: Sub-Saharan Africa (1:1,400)\n  - OCA4: Japan (1:17,000)\n- Cultural beliefs may impact counseling\n\n---\n\n### Epidermolysis Bullosa (EB) ‚≠ê‚≠ê\n**Multiple Types, Different Inheritance**\n\n#### Classification\n1. **EB Simplex**: AD, basal keratinocytes\n2. **Junctional EB**: AR, lamina lucida\n3. **Dystrophic EB**: AD/AR, below lamina densa\n\n#### Key Counseling Points\n- Severity ranges from mild to lethal\n- Prenatal diagnosis via fetal skin biopsy\n- Multidisciplinary care essential\n- Pain management crucial\n- Infection prevention protocols\n\n---",
      "importance": 1
    },
    {
      "id": "skeletalconnective-tissue-disorders",
      "title": "\uddb4 SKELETAL/CONNECTIVE TISSUE DISORDERS",
      "content": "### Osteogenesis Imperfecta (OI) ‚≠ê‚≠ê‚≠ê\n**\"Brittle Bone Disease\"**\n\n#### üîë Key Features (Top 3)\n1. **Multiple fractures** with minimal trauma\n2. **Blue sclerae**\n3. **Short stature**\n\n#### Types (Simplified Classification)\n- **Type I**: Mild, blue sclerae, normal stature, hearing loss (50%)\n- **Type II**: Perinatal lethal, multiple fractures in utero\n- **Type III**: Progressive deforming, very short, triangular face\n- **Type IV**: Moderate severity, normal sclerae, variable short stature\n\n#### üß™ Genetics & Testing\n- **Genes**: COL1A1, COL1A2 (90%, AD)\n- **Rare AR forms**: CRTAP, P3H1, PPIB\n- **Testing**: \n  - Gene panel/sequencing\n  - Biochemical collagen analysis\n  - Prenatal: CVS for known mutations\n\n#### üè• Management\n- **Orthopedic**: Rodding procedures, fracture care\n- **Medical**: Bisphosphonates (controversial)\n- **Rehabilitation**: PT/OT crucial\n- **Psychosocial**: Chronic pain, mobility issues\n\n#### üíé Board Pearls\n- Distinguish from NAI (non-accidental injury)\n- Dentinogenesis imperfecta in Types III, IV\n- Most severe cases are de novo\n- Basilar invagination risk in severe types\n- Variable expressivity even within families\n\n---\n\n### Marfan Syndrome ‚≠ê‚≠ê‚≠ê\n**Systemic Connective Tissue Disorder**\n\n#### üîë Key Features (Top 3)\n1. **Aortic root dilatation** ‚Üí dissection risk\n2. **Ectopia lentis** (upward)\n3. **Marfanoid habitus**\n\n#### üè• Ghent Criteria (Revised)\n**In absence of family history, need:**\n- Aortic dilatation (Z ‚â•2) + Ectopia lentis\n- Aortic dilatation (Z ‚â•2) + FBN1 mutation\n- Aortic dilatation (Z ‚â•2) + Systemic score ‚â•7\n- Ectopia lentis + FBN1 mutation with aortic involvement\n\n#### Systemic Score\n- Wrist AND thumb sign: 3\n- Wrist OR thumb sign: 1\n- Pectus deformity: 2 (carinatum), 1 (excavatum)\n- Hindfoot deformity: 2\n- Pneumothorax: 2\n- Dural ectasia: 2\n- Protrusio acetabuli: 2\n- Reduced US/LS AND increased arm span/height: 1\n- Scoliosis or kyphosis: 1\n- Reduced elbow extension: 1\n- 3/5 facial features: 1\n- Skin striae: 1\n- Myopia >3 diopters: 1\n- Mitral valve prolapse: 1\n\n#### üß™ Genetics & Testing\n- **Gene**: FBN1 (95%)\n- **Inheritance**: AD, 25% de novo\n- **Testing**: \n  - FBN1 sequencing/del-dup\n  - Consider TGFBR1/2 if negative\n\n#### üè• Management\n- **Cardiac**: Annual echo, beta-blockers, activity restriction\n- **Ophthalmology**: Annual exams\n- **Orthopedic**: Scoliosis monitoring\n- **Pregnancy**: High risk, cardiology co-management\n\n#### üíé Board Pearls\n- Lens up (vs homocystinuria: down)\n- Aortic dissection main cause of death\n- Pregnancy increases dissection risk\n- No contact sports\n- Distinguished from Loeys-Dietz by arterial tortuosity\n\n---\n\n### Ehlers-Danlos Syndromes (EDS) ‚≠ê‚≠ê‚≠ê\n**Heterogeneous Group - 13 Types**\n\n#### Major Types for Boards\n\n##### Classical EDS (Types I/II)\n- **Features**: Hyperextensible skin, atrophic scars, joint hypermobility\n- **Genes**: COL5A1, COL5A2\n- **Inheritance**: AD\n- **Complications**: Easy bruising, poor wound healing\n\n##### Vascular EDS (Type IV) - MOST SEVERE\n- **Features**: Thin translucent skin, arterial/organ rupture\n- **Gene**: COL3A1\n- **Inheritance**: AD\n- **Major risks**: \n  - Arterial rupture (median survival 48y)\n  - Uterine rupture in pregnancy\n  - Bowel perforation\n- **Management**: \n  - Avoid contact sports\n  - Careful blood pressure control\n  - High-risk pregnancy management\n\n##### Hypermobile EDS (Type III)\n- **Features**: Joint hypermobility, chronic pain, POTS\n- **Genetics**: Usually clinical diagnosis\n- **Management**: PT, pain management, POTS treatment\n\n#### üíé Board Pearls\n- Vascular type: most serious, specific gene\n- Beighton score for hypermobility\n- Many patients diagnosed late\n- Chronic pain major QOL issue\n- Surgery complications common\n\n---\n\n### Achondroplasia ‚≠ê‚≠ê‚≠ê\n**Most Common Skeletal Dysplasia**\n\n#### üîë Key Features (Top 3)\n1. **Rhizomelic shortening** (proximal > distal)\n2. **Macrocephaly** with frontal bossing\n3. **Trident hands**\n\n#### üè• Clinical Features\n- **Height**: Males ~131cm, Females ~124cm\n- **Complications**: \n  - Foramen magnum stenosis (infant)\n  - Sleep apnea\n  - Otitis media ‚Üí hearing loss\n  - Spinal stenosis (adult)\n  - Obesity\n- **Intelligence**: Normal\n\n#### üß™ Genetics & Testing\n- **Gene**: FGFR3 (99% c.1138G>A)\n- **Inheritance**: AD, 80% de novo\n- **Paternal age effect**: Increased risk\n- **Testing**: Targeted mutation analysis\n\n#### üë∂ Reproductive Counseling\n- **Two affected parents**: \n  - 25% average stature\n  - 50% achondroplasia\n  - 25% homozygous (lethal)\n- **Prenatal diagnosis**: \n  - US findings after 24 weeks\n  - Molecular testing if at risk\n\n#### üíé Board Pearls\n- Homozygous lethal (important for counseling)\n- Growth curves specific for achondroplasia\n- C-section often needed\n- Sleep study in infancy\n- Avoid gymnastics/contact sports\n\n---\n\n### Craniosynostosis Syndromes ‚≠ê‚≠ê\n\n#### Overview\n- **Definition**: Premature fusion of skull sutures\n- **Isolated**: 80-90%\n- **Syndromic**: 10-20%\n\n#### Major Syndromes\n\n##### Apert Syndrome\n- **Features**: Severe syndactyly (\"mitten hands\"), ID common\n- **Gene**: FGFR2\n- **Inheritance**: AD, mostly de novo\n\n##### Crouzon Syndrome\n- **Features**: Normal hands/feet, normal intelligence\n- **Gene**: FGFR2\n- **Note**: Ocular proptosis prominent\n\n##### Pfeiffer Syndrome\n- **Features**: Broad thumbs/toes, variable severity\n- **Gene**: FGFR1 (Type 1), FGFR2 (Types 1-3)\n- **Type 1**: Best prognosis\n\n##### Muenke Syndrome\n- **Features**: Coronal synostosis, normal intelligence, hearing loss\n- **Gene**: FGFR3 (specific mutation)\n- **Note**: Most common syndromic craniosynostosis\n\n#### üíé Board Pearls\n- Advanced paternal age risk factor\n- Increased ICP requires monitoring\n- Multidisciplinary team essential\n- Hearing assessment important\n- Psychosocial support for facial differences\n\n---",
      "importance": 1
    },
    {
      "id": "sensory-disorders",
      "title": "\udc42 SENSORY DISORDERS",
      "content": "### Hereditary Hearing Loss ‚≠ê‚≠ê‚≠ê\n\n#### Classification\n1. **Syndromic** (30%)\n2. **Non-syndromic** (70%)\n   - DFNA: AD\n   - DFNB: AR\n   - DFNX: X-linked\n\n#### Non-syndromic Hearing Loss\n\n##### GJB2-Related (Connexin 26) - MOST COMMON\n- **Inheritance**: AR (DFNB1)\n- **Frequency**: 50% of AR non-syndromic HL\n- **Common mutations**: \n  - 35delG (European)\n  - 167delT (Ashkenazi Jewish)\n  - 235delC (Asian)\n- **Counseling**: May have connexin 30 deletions\n\n#### Syndromic Hearing Loss\n\n##### Usher Syndrome ‚≠ê‚≠ê‚≠ê\n**HL + Retinitis Pigmentosa**\n\n###### Types\n1. **Type 1**: \n   - Profound congenital HL\n   - Vestibular areflexia\n   - RP onset adolescence\n   - Genes: MYO7A (most common), USH1C, CDH23\n\n2. **Type 2**: \n   - Moderate-severe HL\n   - Normal vestibular\n   - RP onset adolescence/adult\n   - Gene: USH2A (most common)\n\n3. **Type 3**: \n   - Progressive HL\n   - Variable vestibular\n   - Variable RP\n   - Gene: CLRN1\n\n###### Counseling Points\n- Leading cause of deaf-blindness\n- Early intervention crucial\n- Mobility training before vision loss\n- Support groups essential\n\n##### Pendred Syndrome ‚≠ê‚≠ê\n- **Features**: HL + thyroid goiter + EVA\n- **Gene**: SLC26A4\n- **Imaging**: Enlarged vestibular aqueduct (EVA)\n- **Note**: Euthyroid goiter\n\n##### Waardenburg Syndrome ‚≠ê‚≠ê\n- **Features**: HL + pigmentary changes\n- **Types**: \n  - Type 1: Dystopia canthorum (PAX3)\n  - Type 2: No dystopia (MITF, others)\n  - Type 3: + limb anomalies (PAX3)\n  - Type 4: + Hirschsprung (SOX10, others)\n- **Key sign**: White forelock, heterochromia\n\n##### Jervell and Lange-Nielsen\n- **Features**: Profound HL + long QT\n- **Genes**: KCNQ1, KCNE1\n- **Inheritance**: AR\n- **Critical**: Cardiac evaluation, beta-blockers\n\n#### Cultural Considerations in Deaf Community\n- **Deaf culture**: View deafness as difference, not disability\n- **Communication**: ASL as primary language\n- **Reproductive choices**: May prefer deaf children\n- **Technology**: Variable acceptance of CI/hearing aids\n- **Counseling approach**: \n  - Respect cultural identity\n  - Provide unbiased information\n  - Include Deaf community resources\n  - Use certified interpreters\n\n#### üíé Board Pearls\n- GJB2 carrier rate: 1:30 (European ancestry)\n- Temporal bone imaging for syndromic forms\n- CMV most common non-genetic cause\n- Aminoglycosides + m.1555A>G = HL\n- Early intervention improves outcomes\n\n---\n\n### Hereditary Vision Loss ‚≠ê‚≠ê\n\n#### Leber Congenital Amaurosis (LCA)\n- **Features**: Severe vision loss at birth\n- **Genes**: >25 genes (CEP290 most common)\n- **Inheritance**: AR\n- **New therapy**: Gene therapy for RPE65\n\n#### Retinitis Pigmentosa (RP)\n- **Features**: Night blindness ‚Üí tunnel vision\n- **Inheritance**: AD, AR, X-linked\n- **Syndromic associations**: \n  - Usher syndrome\n  - Bardet-Biedl syndrome\n  - Refsum disease\n\n---",
      "importance": 1
    },
    {
      "id": "endocrine-disorders",
      "title": "\udd2c ENDOCRINE DISORDERS",
      "content": "### Congenital Adrenal Hyperplasia (CAH) ‚≠ê‚≠ê‚≠ê\n**21-Hydroxylase Deficiency (95%)**\n\n#### üîë Key Features (Top 3)\n1. **Ambiguous genitalia** in females\n2. **Salt-wasting crisis** (if severe)\n3. **Precocious puberty** (if mild)\n\n#### Forms\n1. **Classic Salt-Wasting** (75%)\n   - Complete enzyme deficiency\n   - Life-threatening salt loss\n   - Virilization\n\n2. **Classic Simple Virilizing** (25%)\n   - Partial enzyme deficiency\n   - Virilization only\n   - No salt wasting\n\n3. **Non-classic** (Late-onset)\n   - Mild enzyme deficiency\n   - Hirsutism, irregular menses\n   - Most common form\n\n#### üß™ Newborn Screening & Diagnosis\n- **NBS**: 17-OHP elevated\n- **Confirmatory tests**:\n  - Repeat 17-OHP\n  - ACTH stimulation test\n  - Electrolytes\n  - Genetic testing\n- **False positives**: Prematurity, stress\n\n#### üè• Management\n- **Acute**: IV fluids, hydrocortisone, salt\n- **Chronic**: \n  - Glucocorticoids (hydrocortisone)\n  - Mineralocorticoids (fludrocortisone)\n  - Salt supplementation (infants)\n- **Monitoring**: Growth, bone age, 17-OHP\n\n#### üë∂ Prenatal Management\n- **At-risk pregnancies**: \n  - Dexamethasone starting <9 weeks\n  - CVS/amnio for fetal sex + genotype\n  - Continue dex only for affected females\n- **Controversy**: Prenatal dex treatment risks/benefits\n\n#### üìà Genetics & Carrier Screening\n- **Gene**: CYP21A2\n- **Inheritance**: AR\n- **Carrier frequency**: \n  - General: 1:60\n  - Ashkenazi Jewish: 1:27\n- **Challenges**: Pseudogene complicates testing\n\n#### üíé Board Pearls\n- Most common cause of ambiguous genitalia\n- Salt crisis at 1-3 weeks if undiagnosed\n- Carrier testing difficult due to pseudogene\n- Non-classic form common in AJ population\n- Prenatal treatment controversial\n\n---\n\n### Neonatal Diabetes Mellitus ‚≠ê‚≠ê\n\n#### Types\n1. **Transient** (TNDM)\n   - Resolves by 18 months\n   - May recur in adolescence\n   - 6q24 abnormalities\n\n2. **Permanent** (PNDM)\n   - Lifelong diabetes\n   - KCNJ11, ABCC8 (can use sulfonylureas)\n   - INS mutations\n\n#### Key Features\n- Onset <6 months age\n- Low birth weight/IUGR\n- No autoantibodies\n- Genetic testing changes management\n\n---\n\n### McCune-Albright Syndrome ‚≠ê\n- **Features**: Caf√©-au-lait, fibrous dysplasia, precocious puberty\n- **Genetics**: GNAS somatic mosaicism\n- **Note**: Cannot be inherited (lethal if germline)\n\n---",
      "importance": 1
    },
    {
      "id": "hematological-disorders",
      "title": "\ude78 HEMATOLOGICAL DISORDERS",
      "content": "### Hemoglobinopathies ‚≠ê‚≠ê‚≠ê\n\n#### Population-Based Screening Programs\n**Target Populations & Carrier Rates:**\n- **African/African American**: \n  - Sickle cell trait: 1:10\n  - Œ±-thalassemia trait: 1:30\n- **Mediterranean**: \n  - Œ≤-thalassemia trait: 1:7-30\n- **Southeast Asian**: \n  - Œ±-thalassemia trait: 1:20\n  - Hb E trait: 1:5-10\n- **Middle Eastern**: \n  - Œ≤-thalassemia trait: 1:10-40\n\n#### Sickle Cell Disease ‚≠ê‚≠ê‚≠ê\n\n##### Genotypes & Severity\n- **Hb SS**: Most severe (sickle cell anemia)\n- **Hb SC**: Intermediate severity\n- **Hb S/Œ≤-thal**: Variable (depends on Œ≤+ or Œ≤0)\n- **Hb S/HPFH**: Mild\n\n##### üè• Clinical Complications\n- **Vaso-occlusive crises**: Pain episodes\n- **Acute chest syndrome**: Life-threatening\n- **Stroke**: 11% by age 20\n- **Splenic sequestration**: Early childhood\n- **Infections**: Functional asplenia\n- **Chronic**: Organ damage, leg ulcers\n\n##### üß™ Screening & Diagnosis\n- **NBS**: Hemoglobin electrophoresis/HPLC\n- **Results interpretation**:\n  - FA: Normal\n  - FAS: Sickle trait\n  - FS: Sickle cell disease\n  - FSC: Hb SC disease\n\n##### Management\n- **Prophylaxis**: Penicillin, vaccines\n- **Hydroxyurea**: ‚Üë Hb F\n- **Transfusions**: Stroke prevention\n- **New therapies**: Voxelotor, crizanlizumab\n- **Cure**: BMT, gene therapy trials\n\n##### üë∂ Reproductive Counseling\n- **Carrier √ó Carrier**: 25% affected\n- **Prenatal diagnosis**: CVS/amnio\n- **PGT available**\n- **SCT**: Generally asymptomatic (except extreme conditions)\n\n#### Œ≤-Thalassemia ‚≠ê‚≠ê‚≠ê\n\n##### Classification\n- **Minor**: One mutation, mild anemia\n- **Intermedia**: Two mutations, moderate anemia\n- **Major**: Two mutations, transfusion-dependent\n\n##### üè• Management\n- **Major**: Regular transfusions + chelation\n- **Monitoring**: Iron overload (ferritin, MRI)\n- **Complications**: Growth, endocrine, cardiac\n\n##### Carrier Screening\n- **CBC indices**: MCV <80, MCH <27\n- **Hb electrophoresis**: ‚Üë Hb A2 (>3.5%)\n- **Molecular**: If indices abnormal\n\n#### Œ±-Thalassemia ‚≠ê‚≠ê\n\n##### Genotypes (--/--)\n- **Silent carrier**: -Œ±/Œ±Œ±\n- **Trait**: --/Œ±Œ± or -Œ±/-Œ±\n- **Hb H disease**: --/-Œ±\n- **Hb Bart's**: --/-- (hydrops fetalis)\n\n##### Key Points\n- **Southeast Asian**: -- deletions common\n- **African**: -Œ± deletions common\n- **Bart's hydrops**: Lethal, needs IUT\n- **Carrier detection**: May have normal Hb electrophoresis\n\n#### üíé Board Pearls\n- MCV screening: <80 adults, <70 children\n- Partner testing crucial before prenatal dx\n- Transfusion before Hb electrophoresis masks results\n- Alpha trait + beta trait = normal indices possible\n- Immigration patterns affect screening needs\n\n---\n\n### Bleeding Disorders ‚≠ê‚≠ê‚≠ê\n\n#### Hemophilia A & B ‚≠ê‚≠ê‚≠ê\n**X-linked Recessive**\n\n##### Severity Classification\n- **Severe**: <1% factor activity\n  - Spontaneous bleeds\n  - Joint/muscle hemorrhages\n- **Moderate**: 1-5% activity\n  - Bleeds with minor trauma\n- **Mild**: 5-40% activity\n  - Bleeds with surgery/major trauma\n\n##### üß™ Genetics & Testing\n- **Hemophilia A**: F8 gene\n  - Intron 22 inversion (45% severe)\n  - Intron 1 inversion (5% severe)\n- **Hemophilia B**: F9 gene\n  - Point mutations common\n\n##### üë© Carrier Testing & Counseling\n- **Carriers**: \n  - Usually 50% factor levels\n  - May have bleeding symptoms\n  - Lyonization ‚Üí variable levels\n- **Testing**: \n  - Factor levels (may be normal)\n  - Genetic testing definitive\n\n##### Reproductive Options\n- **Prenatal diagnosis**: CVS/amnio\n- **PGT available**\n- **Sex selection controversial**\n- **Delivery planning**: \n  - Avoid vacuum/forceps\n  - C-section not routine\n  - Cord blood factor levels\n\n##### üíé Board Pearls\n- 30% de novo mutations\n- Inhibitor development major complication\n- Female homozygotes possible (carrier √ó affected)\n- New therapies: Extended half-life factors, gene therapy\n- Carrier factor levels important for surgery/delivery\n\n#### Von Willebrand Disease ‚≠ê‚≠ê\n**Most Common Bleeding Disorder**\n\n##### Types\n- **Type 1** (70%): Partial quantitative deficiency, AD\n- **Type 2** (25%): Qualitative deficiency, AD\n- **Type 3** (5%): Complete deficiency, AR\n\n##### Clinical Features\n- Mucocutaneous bleeding\n- Heavy menstrual bleeding\n- Post-surgical bleeding\n- Type 3: Joint bleeds\n\n##### Testing Challenges\n- Levels vary with stress, hormones\n- ABO blood type affects levels\n- Multiple tests often needed\n\n---\n\n### Hemochromatosis ‚≠ê‚≠ê\n**HFE-Related (Type 1)**\n\n#### üîë Key Features\n- **Iron overload**: Liver, heart, pancreas\n- **Classic triad**: Cirrhosis, diabetes, skin bronzing\n- **Joints**: Arthropathy\n\n#### üß™ Genetics\n- **Gene**: HFE\n- **Common mutations**: \n  - C282Y (Celtic origin)\n  - H63D (lower penetrance)\n- **Genotype-phenotype**:\n  - C282Y/C282Y: Highest risk\n  - C282Y/H63D: Intermediate\n  - H63D/H63D: Low risk\n\n#### Penetrance Issues\n- **C282Y homozygotes**:\n  - Clinical disease: <10% females, ~30% males\n  - Biochemical abnormalities: ~50%\n- **Modifiers**: Gender, alcohol, diet\n\n#### üíé Board Pearls\n- Population screening controversial\n- Family cascade testing recommended\n- Phlebotomy simple, effective treatment\n- Women protected until menopause\n\n---\n\n### Thrombophilia ‚≠ê‚≠ê\n\n#### Factor V Leiden\n- **Most common inherited thrombophilia**\n- **Mutation**: F5 c.1691G>A\n- **Carrier frequency**: \n  - European: 3-8%\n  - Rare in African, Asian\n- **Thrombosis risk**:\n  - Heterozygotes: 3-8x\n  - Homozygotes: 80x\n- **Testing indications**: Personal/family history VTE\n\n#### Counseling Points\n- Most carriers never have clots\n- Environmental factors important\n- Estrogen increases risk\n- Prophylaxis for high-risk situations\n\n---\n\n### Hereditary Hemorrhagic Telangiectasia (HHT) ‚≠ê‚≠ê\n**Osler-Weber-Rendu Syndrome**\n\n#### Clinical Features\n- **Epistaxis**: 90%, often presenting symptom\n- **Telangiectases**: Lips, tongue, fingers\n- **AVMs**: Pulmonary, cerebral, hepatic, GI\n\n#### Genetics\n- **Genes**: ENG (HHT1), ACVRL1 (HHT2), SMAD4\n- **Inheritance**: AD\n- **Penetrance**: Age-dependent, >90% by 40\n\n#### Management\n- Screen for internal AVMs\n- Iron supplementation\n- Genetic testing guides screening\n\n---",
      "importance": 1
    },
    {
      "id": "dna-repairpremature-aging-disorders",
      "title": "DNA REPAIR/PREMATURE AGING DISORDERS",
      "content": "### Bloom Syndrome ‚≠ê‚≠ê\n**Ashkenazi Jewish Founder Mutation**\n\n#### üîë Key Features (Top 3)\n1. **Growth deficiency** (<3rd percentile)\n2. **Butterfly rash** (photosensitive)\n3. **Extreme cancer predisposition**\n\n#### üè• Clinical Features\n- **Growth**: Proportionate dwarfism\n- **Facial**: Long narrow face, prominent nose/ears\n- **Skin**: Telangiectatic erythema\n- **Immune**: Recurrent infections\n- **Fertility**: Males infertile, females subfertile\n- **Cancer**: 50% by age 25 (any type)\n\n#### üß™ Genetics & Testing\n- **Gene**: BLM (RecQ helicase)\n- **Testing**: \n  - Sister chromatid exchanges (‚Üë‚Üë‚Üë)\n  - BLM sequencing\n- **AJ founder**: blmAsh (>95% of AJ mutations)\n- **Carrier frequency (AJ)**: 1:100\n\n#### Cancer Surveillance\n- **Protocol**: \n  - Annual CBC\n  - Stool guaiac\n  - Consider early colonoscopy\n  - Avoid radiation when possible\n\n#### üíé Board Pearls\n- Sister chromatid exchange pathognomonic\n- Only RecQ helicase disorder with cancer predisposition\n- Diabetes common\n- Growth hormone contraindicated\n- AJ carrier screening recommended\n\n---\n\n### Xeroderma Pigmentosum (XP) ‚≠ê‚≠ê\n**Nucleotide Excision Repair Defect**\n\n#### üîë Key Features (Top 3)\n1. **Extreme sun sensitivity**\n2. **Skin cancer by age 10** (1000x risk)\n3. **Progressive neurodegeneration** (30%)\n\n#### Complementation Groups\n- **XP-A through XP-G**: Different genes\n- **XP-V**: Variant (polymerase eta)\n- **XP-A**: Most severe, neurological involvement\n\n#### üè• Management\n- **Strict sun avoidance**: \n  - UV-blocking film on windows\n  - Protective clothing\n  - Nighttime activities\n- **Surveillance**: \n  - Dermatology q3-6 months\n  - Ophthalmology regularly\n- **Vitamin D supplementation**\n\n#### üíé Board Pearls\n- Neurodegeneration not preventable\n- Prenatal diagnosis available\n- Founder mutations in some populations\n- Cockayne syndrome: Related NER defect\n- TTD: \"Brittle hair\" + photosensitivity\n\n---\n\n### Fanconi Anemia (FA) ‚≠ê‚≠ê‚≠ê\n**Chromosomal Instability Syndrome**\n\n#### üîë Key Features (Top 3)\n1. **Bone marrow failure** (90% by age 40)\n2. **Radial ray anomalies**\n3. **Increased cancer risk**\n\n#### üè• Clinical Features\n- **Hematologic**: Pancytopenia, MDS, AML\n- **Skeletal**: Thumb/radius anomalies (50%)\n- **Growth**: Short stature, microcephaly\n- **Skin**: Caf√©-au-lait, hyperpigmentation\n- **GU**: Renal anomalies, hypogonadism\n- **Other**: 30% no physical anomalies\n\n#### üß™ Genetics & Testing\n- **Genes**: >22 genes (FANCA 60-70%)\n- **Testing**: \n  - Chromosome breakage (DEB/MMC)\n  - Gene panel/WES\n- **Special groups**:\n  - FANCD1 = BRCA2\n  - FANCN = PALB2\n\n#### Management & Surveillance\n- **Hematology**: Regular CBC, BMT consideration\n- **Cancer screening**: \n  - Head/neck (annual)\n  - GYN (annual after puberty)\n- **Avoid**: Radiation, alkylating agents\n\n#### üíé Board Pearls\n- DEB test diagnostic gold standard\n- Androgens temporary help for cytopenias\n- HSCT only cure for bone marrow failure\n- Increased toxicity from chemo/radiation\n- VACTERL association overlap\n\n---\n\n### Progeria Syndromes ‚≠ê\n\n#### Hutchinson-Gilford Progeria\n- **Features**: Accelerated aging from infancy\n- **Gene**: LMNA (de novo)\n- **Prognosis**: Death ~13y (cardiac)\n- **New therapy**: Lonafarnib\n\n#### Werner Syndrome\n- **Features**: Adult-onset progeria\n- **Gene**: WRN (RecQ helicase)\n- **Inheritance**: AR\n- **Cancer risk**: Increased\n\n#### Cockayne Syndrome\n- **Features**: Neurodegeneration, dwarfism, photosensitivity\n- **Genes**: ERCC8, ERCC6\n- **Note**: NER defect like XP\n\n---",
      "importance": 1
    },
    {
      "id": "highyield-board-facts",
      "title": "HIGH-YIELD BOARD FACTS",
      "content": "### Population Screening Programs\n1. **Hemoglobinopathies**:\n   - Universal NBS in US\n   - Targeted carrier screening by ethnicity\n   - MCV <80 triggers evaluation\n\n2. **CAH**:\n   - All states screen\n   - 17-OHP primary marker\n   - High false positive in premature infants\n\n3. **Ashkenazi Jewish Panel**:\n   - Includes: Tay-Sachs, Gaucher, Bloom syndrome\n   - Carrier rate: 1:4 for any disorder\n   - Consider expanded panels\n\n### Prenatal Diagnosis Challenges\n1. **Skeletal dysplasias**:\n   - Often not apparent until 3rd trimester\n   - Molecular testing if known mutation\n   - 3D ultrasound helpful\n\n2. **OI Type II**:\n   - Fractures visible on ultrasound\n   - Decreased skull mineralization\n   - Poor prognosis\n\n### Cultural Considerations\n1. **Deaf community**:\n   - May not view deafness as disability\n   - Respect communication preferences\n   - Include deaf genetic counselors\n\n2. **Albinism in Africa**:\n   - Significant stigma/discrimination\n   - Safety concerns\n   - Cultural myths need addressing\n\n### X-linked Counseling\n1. **Carrier manifestations**:\n   - Skewed X-inactivation\n   - Variable expression\n   - Important for medical management\n\n2. **Reproductive options**:\n   - PGT increasingly used\n   - Sex selection controversial\n   - Discuss all options neutrally\n\n### Quality of Life Considerations\n1. **Chronic conditions**:\n   - Pain management crucial\n   - Transition to adult care\n   - Psychosocial support\n\n2. **Visible differences**:\n   - School accommodations\n   - Bullying prevention\n   - Support groups\n\n---",
      "importance": 1
    }
  ],
  "objectives": [],
  "sectionCount": 16,
  "rawContent": "# Topic 6: Specialized Organ Systems - Comprehensive Board Study Guide\n\n## üìñ Quick Navigation\n\n**[‚¨ÜÔ∏è Back to Master Index](study-guide-master-index.md)** | **[‚¨ÖÔ∏è Previous: Metabolic Disorders](topic5-metabolic-disorders.md)**\n\n### üìã Table of Contents\n- [üéØ Learning Objectives](#-learning-objectives)\n- [üìä Overview of Specialized Systems](#-overview-of-specialized-systems)\n- [üé® Dermatologic Disorders](#-dermatologic-disorders)\n  - [Incontinentia Pigmenti (IP) ‚≠ê‚≠ê‚≠ê](#incontinentia-pigmenti-ip-)\n  - [Ectodermal Dysplasias ‚≠ê‚≠ê](#ectodermal-dysplasias-)\n  - [Albinism ‚≠ê‚≠ê](#albinism-)\n  - [Epidermolysis Bullosa (EB) ‚≠ê‚≠ê](#epidermolysis-bullosa-eb-)\n- [ü¶¥ Skeletal/Connective Tissue Disorders](#-skeletalconnective-tissue-disorders)\n  - [Osteogenesis Imperfecta (OI) ‚≠ê‚≠ê‚≠ê](#osteogenesis-imperfecta-oi-)\n  - [Marfan Syndrome ‚≠ê‚≠ê‚≠ê](#marfan-syndrome-)\n  - [Ehlers-Danlos Syndromes (EDS) ‚≠ê‚≠ê‚≠ê](#ehlers-danlos-syndromes-eds-)\n  - [Achondroplasia ‚≠ê‚≠ê‚≠ê](#achondroplasia-)\n- [üëÇ Sensory Disorders](#-sensory-disorders)\n  - [Hereditary Hearing Loss ‚≠ê‚≠ê‚≠ê](#hereditary-hearing-loss-)\n  - [Hereditary Vision Loss ‚≠ê‚≠ê](#hereditary-vision-loss-)\n- [üî¨ Endocrine Disorders](#-endocrine-disorders)\n  - [Congenital Adrenal Hyperplasia (CAH) ‚≠ê‚≠ê‚≠ê](#congenital-adrenal-hyperplasia-cah-)\n- [ü©∏ Hematological Disorders](#-hematological-disorders)\n  - [Hemoglobinopathies ‚≠ê‚≠ê‚≠ê](#hemoglobinopathies-)\n  - [Bleeding Disorders ‚≠ê‚≠ê‚≠ê](#bleeding-disorders-)\n- [üß¨ DNA Repair/Premature Aging Disorders](#-dna-repairpremature-aging-disorders)\n  - [Bloom Syndrome ‚≠ê‚≠ê](#bloom-syndrome-)\n  - [Xeroderma Pigmentosum (XP) ‚≠ê‚≠ê](#xeroderma-pigmentosum-xp-)\n  - [Fanconi Anemia (FA) ‚≠ê‚≠ê‚≠ê](#fanconi-anemia-fa-)\n- [üìã High-Yield Board Facts](#-high-yield-board-facts)\n- [üßÆ Practice Questions](#-practice-questions)\n- [üìù Mnemonics & Memory Aids](#-mnemonics--memory-aids)\n- [‚úÖ Topic 6 Completion Checklist](#-topic-6-completion-checklist)\n\n### üîç Quick Disorder Lookup\n| Disorder | Key Features | Inheritance | Population Risk | Management |\n|----------|--------------|-------------|-----------------|------------|\n| **Incontinentia Pigmenti** | Staged skin lesions, seizures | XLD, male lethal | Sporadic/familial | Neurologic monitoring |\n| **Hypohidrotic ED** | No sweating, teeth/hair abnormal | XLR | 1:100,000 | Heat protection |\n| **Osteogenesis Imperfecta** | Multiple fractures, blue sclerae | AD (mostly) | 1:20,000 | Fracture prevention |\n| **Marfan Syndrome** | Aortic dilatation, lens dislocation | AD | 1:5,000 | Cardiac monitoring |\n| **Achondroplasia** | Rhizomelic dwarfism | AD, de novo | 1:25,000 | Growth monitoring |\n| **GJB2 Hearing Loss** | Congenital deafness | AR | 1:1,000 | Early intervention |\n| **CAH** | Ambiguous genitalia, salt wasting | AR | 1:15,000 | Hormone replacement |\n| **Sickle Cell Disease** | Vaso-occlusive crises | AR | 1:365 (AA) | Hydroxyurea, prophylaxis |\n| **Hemophilia A** | Bleeding, joint hemorrhages | XLR | 1:5,000 males | Factor replacement |\n| **Bloom Syndrome** | Growth deficiency, cancer risk | AR | 1:48,000 (AJ) | Cancer surveillance |\n\n### üèÜ Board Exam Domain Coverage\n- **Primary Domain:** Clinical Genetics (40-50%)\n- **Secondary Domains:** General Genetics/Genomics (15-25%), Psychosocial/Counseling (10-20%)\n- **Difficulty Level:** Intermediate to Advanced\n- **Estimated Study Time:** 12-15 hours\n- **Last Updated:** July 2025\n\n---\n\n## üéØ Learning Objectives\n\nBy the end of this topic, you should be able to:\n\n1. **Identify** population-specific carrier screening programs for hemoglobinopathies and their target populations\n2. **Counsel** families about CAH newborn screening results and follow-up protocols\n3. **Recognize** prenatal diagnosis challenges for skeletal dysplasias on ultrasound\n4. **Apply** genetic counseling principles for sensory impairments while respecting deaf culture\n5. **Evaluate** pregnancy management strategies for women with connective tissue disorders\n6. **Calculate** carrier risks for X-linked bleeding disorders and counsel at-risk family members\n7. **Develop** cancer surveillance protocols for DNA repair disorder patients\n8. **Compare** quality of life considerations across chronic genetic conditions\n9. **Interpret** hemoglobin electrophoresis results and explain implications\n10. **Distinguish** between different types of ectodermal dysplasias and their inheritance patterns\n11. **Assess** reproductive options for couples at risk for severe skeletal dysplasias\n12. **Demonstrate** cultural competency when counseling for sensory and skin disorders\n\n---\n\n## üìä Overview of Specialized Systems\n\n<details>\n<summary><strong>üìã Major Categories Covered</strong> (Click to expand)</summary>\n\n### Major Categories Covered\n1. **Dermatologic Disorders** - Skin, hair, nail abnormalities\n2. **Skeletal/Connective Tissue** - Bone, joint, vessel disorders\n3. **Sensory Disorders** - Vision and hearing impairments\n4. **Endocrine Disorders** - Hormone deficiencies/excess\n5. **Hematological Disorders** - Blood cell/clotting abnormalities\n6. **DNA Repair/Premature Aging** - Cancer predisposition syndromes\n\n### Key Board Exam Themes\n- Population-based screening programs\n- Newborn screening protocols\n- Prenatal diagnosis limitations\n- Cultural considerations in counseling\n- Reproductive planning for chronic conditions\n- Cancer surveillance guidelines\n- Quality of life assessments\n\n</details>\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)**\n\n---\n\n## üé® DERMATOLOGIC DISORDERS\n\n### Incontinentia Pigmenti (IP) ‚≠ê‚≠ê‚≠ê\n**X-linked Dominant with Male Lethality**\n\n#### üîë Key Features (Top 3)\n1. **Staged skin findings** (4 stages)\n2. **Ectodermal dysplasia signs**\n3. **Risk for seizures**\n\n<details>\n<summary><strong>üè• Clinical Features</strong> (Click to expand)</summary>\n\n- **Stage 1 (birth-4mo)**: Linear blistering along Blaschko lines\n- **Stage 2 (2-6mo)**: Warty/verrucous lesions\n- **Stage 3 (6mo-adult)**: Swirling hyperpigmentation\n- **Stage 4 (adult)**: Linear hypopigmentation/atrophy\n- **Ectodermal**: Alopecia, cone-shaped teeth, nail dystrophy\n- **Neurologic**: Seizures (30%), ID if seizures occur\n- **Ocular**: Retinal detachment, vision loss\n\n</details>\n\n<details>\n<summary><strong>üß™ Genetics & Testing</strong> (Click to expand)</summary>\n\n- **Gene**: IKBKG (NEMO) at Xq28\n- **Inheritance**: X-linked dominant\n- **Testing**: \n  - Gene sequencing (65% detection)\n  - Deletion/duplication analysis\n  - Skin biopsy shows eosinophils\n- **Mosaicism**: Common in affected females\n\n</details>\n\n<details>\n<summary><strong>üë∂ Reproductive Counseling</strong> (Click to expand)</summary>\n\n- **Affected females**: \n  - 50% affected daughters (may be milder due to skewing)\n  - 50% affected sons (usually lethal in utero)\n  - 25% unaffected daughters\n  - 25% unaffected sons\n- **Prenatal findings**: Possible male hydrops\n- **X-inactivation**: May ameliorate severity\n\n</details>\n\n#### üíé Board Pearls\n- Blaschko lines = developmental migration patterns\n- Male lethality leads to skewed sex ratio\n- Stages don't always occur in order\n- X-inactivation studies helpful for carriers\n- Consider if multiple miscarriages + skin findings\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Ectodermal Dysplasias](#ectodermal-dysplasias-)**\n\n---\n\n### Ectodermal Dysplasias ‚≠ê‚≠ê\n\n#### Hypohidrotic Ectodermal Dysplasia (HED)\n**X-linked > AR, AD**\n\n##### üîë Key Features (Top 3)\n1. **Absent/reduced sweating** ‚Üí heat intolerance\n2. **Abnormal teeth** (peg-shaped, missing)\n3. **Sparse hair**\n\n##### üè• Clinical Features\n- **Classic triad**: Hypohidrosis, hypotrichosis, hypodontia\n- **Facial**: Frontal bossing, depressed nasal bridge, thick lips\n- **Dangerous**: Hyperthermia risk (especially infants)\n- **Other**: Dry skin, decreased tears, respiratory infections\n\n##### üß™ Genetics & Testing\n- **X-linked (most common)**: EDA gene\n- **AR**: EDAR, EDARADD\n- **AD**: EDAR, EDARADD (less severe)\n- **Carrier females**: May have patchy sweating, dental anomalies\n\n##### üíé Board Pearls\n- Infant boys with \"fever of unknown origin\" ‚Üí check sweating\n- Carrier females: Lyon hypothesis creates mosaic features\n- Dental implants often needed\n- Heat stroke prevention critical\n\n#### Clouston Syndrome (Hidrotic ED)\n**AD, Normal Sweating**\n\n- **Key features**: Normal sweating, total alopecia, nail dystrophy\n- **Gene**: GJB6 (connexin 30)\n- **Distinguishing**: Palmoplantar hyperkeratosis\n- **Board pearl**: They DO sweat (unlike HED)\n\n---\n\n### Albinism ‚≠ê‚≠ê\n\n#### Oculocutaneous Albinism (OCA)\n**AR, Multiple Types**\n\n##### üîë Key Features (Top 3)\n1. **Hypopigmentation** of skin, hair, eyes\n2. **Vision impairment** (nystagmus, photophobia)\n3. **Increased skin cancer risk**\n\n##### Types & Genes\n- **OCA1**: TYR gene\n  - OCA1A: Complete absence of melanin\n  - OCA1B: Some pigment develops with age\n- **OCA2**: OCA2 gene (most common worldwide)\n- **OCA3**: TYRP1 (rare, \"rufous\" albinism in Africa)\n- **OCA4**: SLC45A2 (common in Japan)\n\n##### üè• Management\n- **Ophthalmology**: Regular exams, low vision aids\n- **Dermatology**: Sun protection, skin cancer screening\n- **Psychosocial**: Address stigma, especially in Africa\n\n##### üíé Board Pearls\n- Visual pathway misrouting is pathognomonic\n- Carrier testing difficult due to multiple genes\n- Higher prevalence in certain populations:\n  - OCA2: Sub-Saharan Africa (1:1,400)\n  - OCA4: Japan (1:17,000)\n- Cultural beliefs may impact counseling\n\n---\n\n### Epidermolysis Bullosa (EB) ‚≠ê‚≠ê\n**Multiple Types, Different Inheritance**\n\n#### Classification\n1. **EB Simplex**: AD, basal keratinocytes\n2. **Junctional EB**: AR, lamina lucida\n3. **Dystrophic EB**: AD/AR, below lamina densa\n\n#### Key Counseling Points\n- Severity ranges from mild to lethal\n- Prenatal diagnosis via fetal skin biopsy\n- Multidisciplinary care essential\n- Pain management crucial\n- Infection prevention protocols\n\n---\n\n## ü¶¥ SKELETAL/CONNECTIVE TISSUE DISORDERS\n\n### Osteogenesis Imperfecta (OI) ‚≠ê‚≠ê‚≠ê\n**\"Brittle Bone Disease\"**\n\n#### üîë Key Features (Top 3)\n1. **Multiple fractures** with minimal trauma\n2. **Blue sclerae**\n3. **Short stature**\n\n#### Types (Simplified Classification)\n- **Type I**: Mild, blue sclerae, normal stature, hearing loss (50%)\n- **Type II**: Perinatal lethal, multiple fractures in utero\n- **Type III**: Progressive deforming, very short, triangular face\n- **Type IV**: Moderate severity, normal sclerae, variable short stature\n\n#### üß™ Genetics & Testing\n- **Genes**: COL1A1, COL1A2 (90%, AD)\n- **Rare AR forms**: CRTAP, P3H1, PPIB\n- **Testing**: \n  - Gene panel/sequencing\n  - Biochemical collagen analysis\n  - Prenatal: CVS for known mutations\n\n#### üè• Management\n- **Orthopedic**: Rodding procedures, fracture care\n- **Medical**: Bisphosphonates (controversial)\n- **Rehabilitation**: PT/OT crucial\n- **Psychosocial**: Chronic pain, mobility issues\n\n#### üíé Board Pearls\n- Distinguish from NAI (non-accidental injury)\n- Dentinogenesis imperfecta in Types III, IV\n- Most severe cases are de novo\n- Basilar invagination risk in severe types\n- Variable expressivity even within families\n\n---\n\n### Marfan Syndrome ‚≠ê‚≠ê‚≠ê\n**Systemic Connective Tissue Disorder**\n\n#### üîë Key Features (Top 3)\n1. **Aortic root dilatation** ‚Üí dissection risk\n2. **Ectopia lentis** (upward)\n3. **Marfanoid habitus**\n\n#### üè• Ghent Criteria (Revised)\n**In absence of family history, need:**\n- Aortic dilatation (Z ‚â•2) + Ectopia lentis\n- Aortic dilatation (Z ‚â•2) + FBN1 mutation\n- Aortic dilatation (Z ‚â•2) + Systemic score ‚â•7\n- Ectopia lentis + FBN1 mutation with aortic involvement\n\n#### Systemic Score\n- Wrist AND thumb sign: 3\n- Wrist OR thumb sign: 1\n- Pectus deformity: 2 (carinatum), 1 (excavatum)\n- Hindfoot deformity: 2\n- Pneumothorax: 2\n- Dural ectasia: 2\n- Protrusio acetabuli: 2\n- Reduced US/LS AND increased arm span/height: 1\n- Scoliosis or kyphosis: 1\n- Reduced elbow extension: 1\n- 3/5 facial features: 1\n- Skin striae: 1\n- Myopia >3 diopters: 1\n- Mitral valve prolapse: 1\n\n#### üß™ Genetics & Testing\n- **Gene**: FBN1 (95%)\n- **Inheritance**: AD, 25% de novo\n- **Testing**: \n  - FBN1 sequencing/del-dup\n  - Consider TGFBR1/2 if negative\n\n#### üè• Management\n- **Cardiac**: Annual echo, beta-blockers, activity restriction\n- **Ophthalmology**: Annual exams\n- **Orthopedic**: Scoliosis monitoring\n- **Pregnancy**: High risk, cardiology co-management\n\n#### üíé Board Pearls\n- Lens up (vs homocystinuria: down)\n- Aortic dissection main cause of death\n- Pregnancy increases dissection risk\n- No contact sports\n- Distinguished from Loeys-Dietz by arterial tortuosity\n\n---\n\n### Ehlers-Danlos Syndromes (EDS) ‚≠ê‚≠ê‚≠ê\n**Heterogeneous Group - 13 Types**\n\n#### Major Types for Boards\n\n##### Classical EDS (Types I/II)\n- **Features**: Hyperextensible skin, atrophic scars, joint hypermobility\n- **Genes**: COL5A1, COL5A2\n- **Inheritance**: AD\n- **Complications**: Easy bruising, poor wound healing\n\n##### Vascular EDS (Type IV) - MOST SEVERE\n- **Features**: Thin translucent skin, arterial/organ rupture\n- **Gene**: COL3A1\n- **Inheritance**: AD\n- **Major risks**: \n  - Arterial rupture (median survival 48y)\n  - Uterine rupture in pregnancy\n  - Bowel perforation\n- **Management**: \n  - Avoid contact sports\n  - Careful blood pressure control\n  - High-risk pregnancy management\n\n##### Hypermobile EDS (Type III)\n- **Features**: Joint hypermobility, chronic pain, POTS\n- **Genetics**: Usually clinical diagnosis\n- **Management**: PT, pain management, POTS treatment\n\n#### üíé Board Pearls\n- Vascular type: most serious, specific gene\n- Beighton score for hypermobility\n- Many patients diagnosed late\n- Chronic pain major QOL issue\n- Surgery complications common\n\n---\n\n### Achondroplasia ‚≠ê‚≠ê‚≠ê\n**Most Common Skeletal Dysplasia**\n\n#### üîë Key Features (Top 3)\n1. **Rhizomelic shortening** (proximal > distal)\n2. **Macrocephaly** with frontal bossing\n3. **Trident hands**\n\n#### üè• Clinical Features\n- **Height**: Males ~131cm, Females ~124cm\n- **Complications**: \n  - Foramen magnum stenosis (infant)\n  - Sleep apnea\n  - Otitis media ‚Üí hearing loss\n  - Spinal stenosis (adult)\n  - Obesity\n- **Intelligence**: Normal\n\n#### üß™ Genetics & Testing\n- **Gene**: FGFR3 (99% c.1138G>A)\n- **Inheritance**: AD, 80% de novo\n- **Paternal age effect**: Increased risk\n- **Testing**: Targeted mutation analysis\n\n#### üë∂ Reproductive Counseling\n- **Two affected parents**: \n  - 25% average stature\n  - 50% achondroplasia\n  - 25% homozygous (lethal)\n- **Prenatal diagnosis**: \n  - US findings after 24 weeks\n  - Molecular testing if at risk\n\n#### üíé Board Pearls\n- Homozygous lethal (important for counseling)\n- Growth curves specific for achondroplasia\n- C-section often needed\n- Sleep study in infancy\n- Avoid gymnastics/contact sports\n\n---\n\n### Craniosynostosis Syndromes ‚≠ê‚≠ê\n\n#### Overview\n- **Definition**: Premature fusion of skull sutures\n- **Isolated**: 80-90%\n- **Syndromic**: 10-20%\n\n#### Major Syndromes\n\n##### Apert Syndrome\n- **Features**: Severe syndactyly (\"mitten hands\"), ID common\n- **Gene**: FGFR2\n- **Inheritance**: AD, mostly de novo\n\n##### Crouzon Syndrome\n- **Features**: Normal hands/feet, normal intelligence\n- **Gene**: FGFR2\n- **Note**: Ocular proptosis prominent\n\n##### Pfeiffer Syndrome\n- **Features**: Broad thumbs/toes, variable severity\n- **Gene**: FGFR1 (Type 1), FGFR2 (Types 1-3)\n- **Type 1**: Best prognosis\n\n##### Muenke Syndrome\n- **Features**: Coronal synostosis, normal intelligence, hearing loss\n- **Gene**: FGFR3 (specific mutation)\n- **Note**: Most common syndromic craniosynostosis\n\n#### üíé Board Pearls\n- Advanced paternal age risk factor\n- Increased ICP requires monitoring\n- Multidisciplinary team essential\n- Hearing assessment important\n- Psychosocial support for facial differences\n\n---\n\n## üëÇ SENSORY DISORDERS\n\n### Hereditary Hearing Loss ‚≠ê‚≠ê‚≠ê\n\n#### Classification\n1. **Syndromic** (30%)\n2. **Non-syndromic** (70%)\n   - DFNA: AD\n   - DFNB: AR\n   - DFNX: X-linked\n\n#### Non-syndromic Hearing Loss\n\n##### GJB2-Related (Connexin 26) - MOST COMMON\n- **Inheritance**: AR (DFNB1)\n- **Frequency**: 50% of AR non-syndromic HL\n- **Common mutations**: \n  - 35delG (European)\n  - 167delT (Ashkenazi Jewish)\n  - 235delC (Asian)\n- **Counseling**: May have connexin 30 deletions\n\n#### Syndromic Hearing Loss\n\n##### Usher Syndrome ‚≠ê‚≠ê‚≠ê\n**HL + Retinitis Pigmentosa**\n\n###### Types\n1. **Type 1**: \n   - Profound congenital HL\n   - Vestibular areflexia\n   - RP onset adolescence\n   - Genes: MYO7A (most common), USH1C, CDH23\n\n2. **Type 2**: \n   - Moderate-severe HL\n   - Normal vestibular\n   - RP onset adolescence/adult\n   - Gene: USH2A (most common)\n\n3. **Type 3**: \n   - Progressive HL\n   - Variable vestibular\n   - Variable RP\n   - Gene: CLRN1\n\n###### Counseling Points\n- Leading cause of deaf-blindness\n- Early intervention crucial\n- Mobility training before vision loss\n- Support groups essential\n\n##### Pendred Syndrome ‚≠ê‚≠ê\n- **Features**: HL + thyroid goiter + EVA\n- **Gene**: SLC26A4\n- **Imaging**: Enlarged vestibular aqueduct (EVA)\n- **Note**: Euthyroid goiter\n\n##### Waardenburg Syndrome ‚≠ê‚≠ê\n- **Features**: HL + pigmentary changes\n- **Types**: \n  - Type 1: Dystopia canthorum (PAX3)\n  - Type 2: No dystopia (MITF, others)\n  - Type 3: + limb anomalies (PAX3)\n  - Type 4: + Hirschsprung (SOX10, others)\n- **Key sign**: White forelock, heterochromia\n\n##### Jervell and Lange-Nielsen\n- **Features**: Profound HL + long QT\n- **Genes**: KCNQ1, KCNE1\n- **Inheritance**: AR\n- **Critical**: Cardiac evaluation, beta-blockers\n\n#### Cultural Considerations in Deaf Community\n- **Deaf culture**: View deafness as difference, not disability\n- **Communication**: ASL as primary language\n- **Reproductive choices**: May prefer deaf children\n- **Technology**: Variable acceptance of CI/hearing aids\n- **Counseling approach**: \n  - Respect cultural identity\n  - Provide unbiased information\n  - Include Deaf community resources\n  - Use certified interpreters\n\n#### üíé Board Pearls\n- GJB2 carrier rate: 1:30 (European ancestry)\n- Temporal bone imaging for syndromic forms\n- CMV most common non-genetic cause\n- Aminoglycosides + m.1555A>G = HL\n- Early intervention improves outcomes\n\n---\n\n### Hereditary Vision Loss ‚≠ê‚≠ê\n\n#### Leber Congenital Amaurosis (LCA)\n- **Features**: Severe vision loss at birth\n- **Genes**: >25 genes (CEP290 most common)\n- **Inheritance**: AR\n- **New therapy**: Gene therapy for RPE65\n\n#### Retinitis Pigmentosa (RP)\n- **Features**: Night blindness ‚Üí tunnel vision\n- **Inheritance**: AD, AR, X-linked\n- **Syndromic associations**: \n  - Usher syndrome\n  - Bardet-Biedl syndrome\n  - Refsum disease\n\n---\n\n## üî¨ ENDOCRINE DISORDERS\n\n### Congenital Adrenal Hyperplasia (CAH) ‚≠ê‚≠ê‚≠ê\n**21-Hydroxylase Deficiency (95%)**\n\n#### üîë Key Features (Top 3)\n1. **Ambiguous genitalia** in females\n2. **Salt-wasting crisis** (if severe)\n3. **Precocious puberty** (if mild)\n\n#### Forms\n1. **Classic Salt-Wasting** (75%)\n   - Complete enzyme deficiency\n   - Life-threatening salt loss\n   - Virilization\n\n2. **Classic Simple Virilizing** (25%)\n   - Partial enzyme deficiency\n   - Virilization only\n   - No salt wasting\n\n3. **Non-classic** (Late-onset)\n   - Mild enzyme deficiency\n   - Hirsutism, irregular menses\n   - Most common form\n\n#### üß™ Newborn Screening & Diagnosis\n- **NBS**: 17-OHP elevated\n- **Confirmatory tests**:\n  - Repeat 17-OHP\n  - ACTH stimulation test\n  - Electrolytes\n  - Genetic testing\n- **False positives**: Prematurity, stress\n\n#### üè• Management\n- **Acute**: IV fluids, hydrocortisone, salt\n- **Chronic**: \n  - Glucocorticoids (hydrocortisone)\n  - Mineralocorticoids (fludrocortisone)\n  - Salt supplementation (infants)\n- **Monitoring**: Growth, bone age, 17-OHP\n\n#### üë∂ Prenatal Management\n- **At-risk pregnancies**: \n  - Dexamethasone starting <9 weeks\n  - CVS/amnio for fetal sex + genotype\n  - Continue dex only for affected females\n- **Controversy**: Prenatal dex treatment risks/benefits\n\n#### üìà Genetics & Carrier Screening\n- **Gene**: CYP21A2\n- **Inheritance**: AR\n- **Carrier frequency**: \n  - General: 1:60\n  - Ashkenazi Jewish: 1:27\n- **Challenges**: Pseudogene complicates testing\n\n#### üíé Board Pearls\n- Most common cause of ambiguous genitalia\n- Salt crisis at 1-3 weeks if undiagnosed\n- Carrier testing difficult due to pseudogene\n- Non-classic form common in AJ population\n- Prenatal treatment controversial\n\n---\n\n### Neonatal Diabetes Mellitus ‚≠ê‚≠ê\n\n#### Types\n1. **Transient** (TNDM)\n   - Resolves by 18 months\n   - May recur in adolescence\n   - 6q24 abnormalities\n\n2. **Permanent** (PNDM)\n   - Lifelong diabetes\n   - KCNJ11, ABCC8 (can use sulfonylureas)\n   - INS mutations\n\n#### Key Features\n- Onset <6 months age\n- Low birth weight/IUGR\n- No autoantibodies\n- Genetic testing changes management\n\n---\n\n### McCune-Albright Syndrome ‚≠ê\n- **Features**: Caf√©-au-lait, fibrous dysplasia, precocious puberty\n- **Genetics**: GNAS somatic mosaicism\n- **Note**: Cannot be inherited (lethal if germline)\n\n---\n\n## ü©∏ HEMATOLOGICAL DISORDERS\n\n### Hemoglobinopathies ‚≠ê‚≠ê‚≠ê\n\n#### Population-Based Screening Programs\n**Target Populations & Carrier Rates:**\n- **African/African American**: \n  - Sickle cell trait: 1:10\n  - Œ±-thalassemia trait: 1:30\n- **Mediterranean**: \n  - Œ≤-thalassemia trait: 1:7-30\n- **Southeast Asian**: \n  - Œ±-thalassemia trait: 1:20\n  - Hb E trait: 1:5-10\n- **Middle Eastern**: \n  - Œ≤-thalassemia trait: 1:10-40\n\n#### Sickle Cell Disease ‚≠ê‚≠ê‚≠ê\n\n##### Genotypes & Severity\n- **Hb SS**: Most severe (sickle cell anemia)\n- **Hb SC**: Intermediate severity\n- **Hb S/Œ≤-thal**: Variable (depends on Œ≤+ or Œ≤0)\n- **Hb S/HPFH**: Mild\n\n##### üè• Clinical Complications\n- **Vaso-occlusive crises**: Pain episodes\n- **Acute chest syndrome**: Life-threatening\n- **Stroke**: 11% by age 20\n- **Splenic sequestration**: Early childhood\n- **Infections**: Functional asplenia\n- **Chronic**: Organ damage, leg ulcers\n\n##### üß™ Screening & Diagnosis\n- **NBS**: Hemoglobin electrophoresis/HPLC\n- **Results interpretation**:\n  - FA: Normal\n  - FAS: Sickle trait\n  - FS: Sickle cell disease\n  - FSC: Hb SC disease\n\n##### Management\n- **Prophylaxis**: Penicillin, vaccines\n- **Hydroxyurea**: ‚Üë Hb F\n- **Transfusions**: Stroke prevention\n- **New therapies**: Voxelotor, crizanlizumab\n- **Cure**: BMT, gene therapy trials\n\n##### üë∂ Reproductive Counseling\n- **Carrier √ó Carrier**: 25% affected\n- **Prenatal diagnosis**: CVS/amnio\n- **PGT available**\n- **SCT**: Generally asymptomatic (except extreme conditions)\n\n#### Œ≤-Thalassemia ‚≠ê‚≠ê‚≠ê\n\n##### Classification\n- **Minor**: One mutation, mild anemia\n- **Intermedia**: Two mutations, moderate anemia\n- **Major**: Two mutations, transfusion-dependent\n\n##### üè• Management\n- **Major**: Regular transfusions + chelation\n- **Monitoring**: Iron overload (ferritin, MRI)\n- **Complications**: Growth, endocrine, cardiac\n\n##### Carrier Screening\n- **CBC indices**: MCV <80, MCH <27\n- **Hb electrophoresis**: ‚Üë Hb A2 (>3.5%)\n- **Molecular**: If indices abnormal\n\n#### Œ±-Thalassemia ‚≠ê‚≠ê\n\n##### Genotypes (--/--)\n- **Silent carrier**: -Œ±/Œ±Œ±\n- **Trait**: --/Œ±Œ± or -Œ±/-Œ±\n- **Hb H disease**: --/-Œ±\n- **Hb Bart's**: --/-- (hydrops fetalis)\n\n##### Key Points\n- **Southeast Asian**: -- deletions common\n- **African**: -Œ± deletions common\n- **Bart's hydrops**: Lethal, needs IUT\n- **Carrier detection**: May have normal Hb electrophoresis\n\n#### üíé Board Pearls\n- MCV screening: <80 adults, <70 children\n- Partner testing crucial before prenatal dx\n- Transfusion before Hb electrophoresis masks results\n- Alpha trait + beta trait = normal indices possible\n- Immigration patterns affect screening needs\n\n---\n\n### Bleeding Disorders ‚≠ê‚≠ê‚≠ê\n\n#### Hemophilia A & B ‚≠ê‚≠ê‚≠ê\n**X-linked Recessive**\n\n##### Severity Classification\n- **Severe**: <1% factor activity\n  - Spontaneous bleeds\n  - Joint/muscle hemorrhages\n- **Moderate**: 1-5% activity\n  - Bleeds with minor trauma\n- **Mild**: 5-40% activity\n  - Bleeds with surgery/major trauma\n\n##### üß™ Genetics & Testing\n- **Hemophilia A**: F8 gene\n  - Intron 22 inversion (45% severe)\n  - Intron 1 inversion (5% severe)\n- **Hemophilia B**: F9 gene\n  - Point mutations common\n\n##### üë© Carrier Testing & Counseling\n- **Carriers**: \n  - Usually 50% factor levels\n  - May have bleeding symptoms\n  - Lyonization ‚Üí variable levels\n- **Testing**: \n  - Factor levels (may be normal)\n  - Genetic testing definitive\n\n##### Reproductive Options\n- **Prenatal diagnosis**: CVS/amnio\n- **PGT available**\n- **Sex selection controversial**\n- **Delivery planning**: \n  - Avoid vacuum/forceps\n  - C-section not routine\n  - Cord blood factor levels\n\n##### üíé Board Pearls\n- 30% de novo mutations\n- Inhibitor development major complication\n- Female homozygotes possible (carrier √ó affected)\n- New therapies: Extended half-life factors, gene therapy\n- Carrier factor levels important for surgery/delivery\n\n#### Von Willebrand Disease ‚≠ê‚≠ê\n**Most Common Bleeding Disorder**\n\n##### Types\n- **Type 1** (70%): Partial quantitative deficiency, AD\n- **Type 2** (25%): Qualitative deficiency, AD\n- **Type 3** (5%): Complete deficiency, AR\n\n##### Clinical Features\n- Mucocutaneous bleeding\n- Heavy menstrual bleeding\n- Post-surgical bleeding\n- Type 3: Joint bleeds\n\n##### Testing Challenges\n- Levels vary with stress, hormones\n- ABO blood type affects levels\n- Multiple tests often needed\n\n---\n\n### Hemochromatosis ‚≠ê‚≠ê\n**HFE-Related (Type 1)**\n\n#### üîë Key Features\n- **Iron overload**: Liver, heart, pancreas\n- **Classic triad**: Cirrhosis, diabetes, skin bronzing\n- **Joints**: Arthropathy\n\n#### üß™ Genetics\n- **Gene**: HFE\n- **Common mutations**: \n  - C282Y (Celtic origin)\n  - H63D (lower penetrance)\n- **Genotype-phenotype**:\n  - C282Y/C282Y: Highest risk\n  - C282Y/H63D: Intermediate\n  - H63D/H63D: Low risk\n\n#### Penetrance Issues\n- **C282Y homozygotes**:\n  - Clinical disease: <10% females, ~30% males\n  - Biochemical abnormalities: ~50%\n- **Modifiers**: Gender, alcohol, diet\n\n#### üíé Board Pearls\n- Population screening controversial\n- Family cascade testing recommended\n- Phlebotomy simple, effective treatment\n- Women protected until menopause\n\n---\n\n### Thrombophilia ‚≠ê‚≠ê\n\n#### Factor V Leiden\n- **Most common inherited thrombophilia**\n- **Mutation**: F5 c.1691G>A\n- **Carrier frequency**: \n  - European: 3-8%\n  - Rare in African, Asian\n- **Thrombosis risk**:\n  - Heterozygotes: 3-8x\n  - Homozygotes: 80x\n- **Testing indications**: Personal/family history VTE\n\n#### Counseling Points\n- Most carriers never have clots\n- Environmental factors important\n- Estrogen increases risk\n- Prophylaxis for high-risk situations\n\n---\n\n### Hereditary Hemorrhagic Telangiectasia (HHT) ‚≠ê‚≠ê\n**Osler-Weber-Rendu Syndrome**\n\n#### Clinical Features\n- **Epistaxis**: 90%, often presenting symptom\n- **Telangiectases**: Lips, tongue, fingers\n- **AVMs**: Pulmonary, cerebral, hepatic, GI\n\n#### Genetics\n- **Genes**: ENG (HHT1), ACVRL1 (HHT2), SMAD4\n- **Inheritance**: AD\n- **Penetrance**: Age-dependent, >90% by 40\n\n#### Management\n- Screen for internal AVMs\n- Iron supplementation\n- Genetic testing guides screening\n\n---\n\n## üß¨ DNA REPAIR/PREMATURE AGING DISORDERS\n\n### Bloom Syndrome ‚≠ê‚≠ê\n**Ashkenazi Jewish Founder Mutation**\n\n#### üîë Key Features (Top 3)\n1. **Growth deficiency** (<3rd percentile)\n2. **Butterfly rash** (photosensitive)\n3. **Extreme cancer predisposition**\n\n#### üè• Clinical Features\n- **Growth**: Proportionate dwarfism\n- **Facial**: Long narrow face, prominent nose/ears\n- **Skin**: Telangiectatic erythema\n- **Immune**: Recurrent infections\n- **Fertility**: Males infertile, females subfertile\n- **Cancer**: 50% by age 25 (any type)\n\n#### üß™ Genetics & Testing\n- **Gene**: BLM (RecQ helicase)\n- **Testing**: \n  - Sister chromatid exchanges (‚Üë‚Üë‚Üë)\n  - BLM sequencing\n- **AJ founder**: blmAsh (>95% of AJ mutations)\n- **Carrier frequency (AJ)**: 1:100\n\n#### Cancer Surveillance\n- **Protocol**: \n  - Annual CBC\n  - Stool guaiac\n  - Consider early colonoscopy\n  - Avoid radiation when possible\n\n#### üíé Board Pearls\n- Sister chromatid exchange pathognomonic\n- Only RecQ helicase disorder with cancer predisposition\n- Diabetes common\n- Growth hormone contraindicated\n- AJ carrier screening recommended\n\n---\n\n### Xeroderma Pigmentosum (XP) ‚≠ê‚≠ê\n**Nucleotide Excision Repair Defect**\n\n#### üîë Key Features (Top 3)\n1. **Extreme sun sensitivity**\n2. **Skin cancer by age 10** (1000x risk)\n3. **Progressive neurodegeneration** (30%)\n\n#### Complementation Groups\n- **XP-A through XP-G**: Different genes\n- **XP-V**: Variant (polymerase eta)\n- **XP-A**: Most severe, neurological involvement\n\n#### üè• Management\n- **Strict sun avoidance**: \n  - UV-blocking film on windows\n  - Protective clothing\n  - Nighttime activities\n- **Surveillance**: \n  - Dermatology q3-6 months\n  - Ophthalmology regularly\n- **Vitamin D supplementation**\n\n#### üíé Board Pearls\n- Neurodegeneration not preventable\n- Prenatal diagnosis available\n- Founder mutations in some populations\n- Cockayne syndrome: Related NER defect\n- TTD: \"Brittle hair\" + photosensitivity\n\n---\n\n### Fanconi Anemia (FA) ‚≠ê‚≠ê‚≠ê\n**Chromosomal Instability Syndrome**\n\n#### üîë Key Features (Top 3)\n1. **Bone marrow failure** (90% by age 40)\n2. **Radial ray anomalies**\n3. **Increased cancer risk**\n\n#### üè• Clinical Features\n- **Hematologic**: Pancytopenia, MDS, AML\n- **Skeletal**: Thumb/radius anomalies (50%)\n- **Growth**: Short stature, microcephaly\n- **Skin**: Caf√©-au-lait, hyperpigmentation\n- **GU**: Renal anomalies, hypogonadism\n- **Other**: 30% no physical anomalies\n\n#### üß™ Genetics & Testing\n- **Genes**: >22 genes (FANCA 60-70%)\n- **Testing**: \n  - Chromosome breakage (DEB/MMC)\n  - Gene panel/WES\n- **Special groups**:\n  - FANCD1 = BRCA2\n  - FANCN = PALB2\n\n#### Management & Surveillance\n- **Hematology**: Regular CBC, BMT consideration\n- **Cancer screening**: \n  - Head/neck (annual)\n  - GYN (annual after puberty)\n- **Avoid**: Radiation, alkylating agents\n\n#### üíé Board Pearls\n- DEB test diagnostic gold standard\n- Androgens temporary help for cytopenias\n- HSCT only cure for bone marrow failure\n- Increased toxicity from chemo/radiation\n- VACTERL association overlap\n\n---\n\n### Progeria Syndromes ‚≠ê\n\n#### Hutchinson-Gilford Progeria\n- **Features**: Accelerated aging from infancy\n- **Gene**: LMNA (de novo)\n- **Prognosis**: Death ~13y (cardiac)\n- **New therapy**: Lonafarnib\n\n#### Werner Syndrome\n- **Features**: Adult-onset progeria\n- **Gene**: WRN (RecQ helicase)\n- **Inheritance**: AR\n- **Cancer risk**: Increased\n\n#### Cockayne Syndrome\n- **Features**: Neurodegeneration, dwarfism, photosensitivity\n- **Genes**: ERCC8, ERCC6\n- **Note**: NER defect like XP\n\n---\n\n## üìã HIGH-YIELD BOARD FACTS\n\n### Population Screening Programs\n1. **Hemoglobinopathies**:\n   - Universal NBS in US\n   - Targeted carrier screening by ethnicity\n   - MCV <80 triggers evaluation\n\n2. **CAH**:\n   - All states screen\n   - 17-OHP primary marker\n   - High false positive in premature infants\n\n3. **Ashkenazi Jewish Panel**:\n   - Includes: Tay-Sachs, Gaucher, Bloom syndrome\n   - Carrier rate: 1:4 for any disorder\n   - Consider expanded panels\n\n### Prenatal Diagnosis Challenges\n1. **Skeletal dysplasias**:\n   - Often not apparent until 3rd trimester\n   - Molecular testing if known mutation\n   - 3D ultrasound helpful\n\n2. **OI Type II**:\n   - Fractures visible on ultrasound\n   - Decreased skull mineralization\n   - Poor prognosis\n\n### Cultural Considerations\n1. **Deaf community**:\n   - May not view deafness as disability\n   - Respect communication preferences\n   - Include deaf genetic counselors\n\n2. **Albinism in Africa**:\n   - Significant stigma/discrimination\n   - Safety concerns\n   - Cultural myths need addressing\n\n### X-linked Counseling\n1. **Carrier manifestations**:\n   - Skewed X-inactivation\n   - Variable expression\n   - Important for medical management\n\n2. **Reproductive options**:\n   - PGT increasingly used\n   - Sex selection controversial\n   - Discuss all options neutrally\n\n### Quality of Life Considerations\n1. **Chronic conditions**:\n   - Pain management crucial\n   - Transition to adult care\n   - Psychosocial support\n\n2. **Visible differences**:\n   - School accommodations\n   - Bullying prevention\n   - Support groups\n\n---\n\n## üßÆ PRACTICE QUESTIONS\n\n### Question 1\nA couple of Mediterranean ancestry requests carrier screening. The woman's CBC shows: Hgb 11.5 g/dL, MCV 72 fL. The man's CBC is normal. What is the most appropriate next step?\n\nA) Reassure that only one partner needs testing\nB) Order hemoglobin electrophoresis on the woman\nC) Order molecular testing for Œ≤-thalassemia\nD) Recommend prenatal diagnosis\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: B**\n- Low MCV suggests possible thalassemia trait\n- Hemoglobin electrophoresis can identify Œ≤-thalassemia trait (elevated Hb A2)\n- Partner testing depends on woman's results\n</details>\n\n### Question 2\nA pregnant woman is a carrier for hemophilia A. Her partner is unaffected. CVS shows a 46,XY karyotype. What is the risk the fetus is affected?\n\nA) 0%\nB) 25%\nC) 50%\nD) 100%\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: C**\n- X-linked recessive inheritance\n- Male fetus has 50% chance of inheriting mutation\n- Would be affected if inherits mutation\n</details>\n\n### Question 3\nParents of a child with osteogenesis imperfecta type II (perinatal lethal) request recurrence risk counseling. Neither parent is affected. What is the most likely recurrence risk?\n\nA) <1%\nB) 25%\nC) 50%\nD) 67%\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: A**\n- OI type II usually due to de novo dominant mutations\n- Small risk due to gonadal mosaicism\n- Prenatal diagnosis recommended for reassurance\n</details>\n\n### Question 4\nA 6-month-old boy presents with blistering along linear patterns on his trunk. His mother had similar lesions as an infant that resolved. What is the most likely diagnosis?\n\nA) Epidermolysis bullosa\nB) Incontinentia pigmenti\nC) Bloom syndrome\nD) Xeroderma pigmentosum\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: B**\n- Linear blistering following Blaschko lines\n- X-linked dominant with male lethality\n- Mother likely has mild manifestations due to X-inactivation\n</details>\n\n### Question 5\nA couple requests genetic counseling after their daughter was diagnosed with congenital profound hearing loss. Testing reveals she is homozygous for GJB2 mutations. What is the chance their next child will have hearing loss?\n\nA) 0%\nB) 25%\nC) 50%\nD) 100%\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: B**\n- Autosomal recessive inheritance\n- Both parents are carriers\n- 25% recurrence risk\n</details>\n\n---\n\n## üìù MNEMONICS & MEMORY AIDS\n\n### \"SKIN\" - Ectodermal Dysplasia Features\n- **S**weat glands absent/reduced\n- **K**eratinization abnormal (skin/nails)\n- **I**ncisors peg-shaped\n- **N**umber of teeth reduced\n\n### \"MARFAN\" - Major Features\n- **M**yopia\n- **A**ortic dilatation\n- **R**etinal detachment risk\n- **F**ingers long (arachnodactyly)\n- **A**rm span > height\n- **N**o intellectual disability\n\n### \"BLEEDS\" - Von Willebrand Disease\n- **B**ruising easy\n- **L**ong bleeding time\n- **E**pistaxis frequent\n- **E**ndometrial bleeding heavy\n- **D**ental bleeding prolonged\n- **S**urgical bleeding risk\n\n### \"HIT SCAFFOLD\" - OI Features\n- **H**earing loss\n- **I**ncreased fractures\n- **T**eeth (dentinogenesis imperfecta)\n- **S**clera blue\n- **C**ollagen defect\n- **A**utosomal dominant\n- **F**ractures in utero (type II)\n- **F**amily history often negative\n- **O**steogenesis imperfecta\n- **L**ow trauma fractures\n- **D**eformities progressive\n\n---\n\n## ‚úÖ Topic 6 Completion Checklist\n\n### ‚úÖ Core Knowledge Areas\n- [ ] Population-specific hemoglobinopathy screening programs\n- [ ] CAH newborn screening interpretation and follow-up\n- [ ] Prenatal diagnosis limitations for skeletal dysplasias\n- [ ] Cultural considerations in deaf community counseling\n- [ ] Pregnancy management in connective tissue disorders\n- [ ] X-linked bleeding disorder carrier counseling\n- [ ] DNA repair disorder cancer surveillance protocols\n- [ ] Quality of life considerations in chronic conditions\n- [ ] Incontinentia pigmenti stages and X-linked dominant inheritance\n- [ ] Ectodermal dysplasia hypohidrosis vs hidrotic types\n\n### üéØ Clinical Skills\n- [ ] Can interpret CBC indices for thalassemia screening\n- [ ] Understand X-linked inheritance risks and carrier manifestations\n- [ ] Recognize syndromic vs non-syndromic hearing loss patterns\n- [ ] Apply cultural competency in sensory impairment counseling\n- [ ] Calculate bleeding disorder risks and counsel families\n- [ ] Assess fracture patterns and distinguish from abuse\n- [ ] Evaluate growth patterns in skeletal dysplasias\n- [ ] Apply Ghent criteria for Marfan syndrome diagnosis\n\n### üìö Test Preparation\n- [ ] Completed all practice questions successfully\n- [ ] Reviewed mnemonics and memory aids\n- [ ] Know population-specific carrier frequencies\n- [ ] Understand genotype-phenotype correlations\n- [ ] Memorized surveillance protocols and management\n- [ ] Created flashcards for key clinical features\n\n### üîÑ Final Review\n- [ ] Cross-referenced with population screening guidelines\n- [ ] Verified cultural considerations for various conditions\n- [ ] Confirmed prenatal diagnosis approaches and limitations\n- [ ] Reviewed multidisciplinary care requirements\n\n---\n\n## üéì Key Takeaway Messages\n\n1. **Population screening** programs target specific ethnicities based on disease prevalence\n2. **Cultural competency** is essential, especially for deaf community counseling\n3. **X-linked inheritance** patterns affect carrier manifestations and reproductive counseling\n4. **Prenatal diagnosis** has limitations for many skeletal and skin conditions\n5. **Quality of life** considerations are paramount in chronic genetic conditions\n6. **Multidisciplinary care** is required for most complex genetic disorders\n7. **Cancer surveillance** protocols are evolving for DNA repair disorders\n8. **Early identification** and intervention improve outcomes in sensory disorders\n9. **Psychosocial support** is crucial for visible differences and chronic conditions\n10. **Family counseling** must address both medical and social implications\n\n---\n\n## üîó Navigation\n\n**[‚¨ÜÔ∏è Back to Master Index](study-guide-master-index.md)** | **[‚¨ÖÔ∏è Previous: Metabolic Disorders](topic5-metabolic-disorders.md)**\n\n---\n\n**üïí Study Time Recommendation:** 12-15 hours  \n**üóìÔ∏è Review Schedule:** Review all topics systematically before exam\n\n**üèÜ Completion Status:** Topic 6 of 6 complete - STUDY GUIDE COMPLETE! üéâ\n\n---\n\n## üéä Congratulations on Completing the Comprehensive Board Study Guide!\n\nYou have now completed all 6 major topic areas for the genetic counseling board exam:\n\n1. ‚úÖ **Topic 1:** Foundation Genetics - Chromosomal Disorders\n2. ‚úÖ **Topic 2:** Cancer Genetics - Hereditary Cancer Syndromes  \n3. ‚úÖ **Topic 3:** Organ System Disorders Part A\n4. ‚úÖ **Topic 4:** Neurological, Neuromuscular & Developmental Disorders\n5. ‚úÖ **Topic 5:** Inborn Errors of Metabolism\n6. ‚úÖ **Topic 6:** Specialized Organ Systems\n\n### üèÜ Final Exam Preparation Tips:\n- **Review systematically** - Use the completion checklists for each topic\n- **Practice calculations** - Risk assessments, carrier frequencies, recurrence risks\n- **Focus on high-yield facts** - Population screening, inheritance patterns, management\n- **Consider psychosocial aspects** - Cultural competency, quality of life, family dynamics\n- **Use active recall** - Test yourself without looking at answers first\n- **Join study groups** - Discuss complex cases and scenarios\n\n**Remember:** This guide covers testable material for the genetic counseling board exam. Focus on recognition patterns, inheritance risks, and counseling strategies rather than detailed molecular mechanisms.\n\n**Good luck with your studies and board exam!** üß¨‚ú®"
}